The ACTC1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population in which the ACTC1 gene has been disrupted to abolish alpha-cardiac actin expression. Generated in HEK293T human embryonic kidney cells, this loss-of-function model is ideal for studying ACTC1-dependent cytoskeletal dynamics and protein interactions in a polyclonal, heterogeneous background.
The HEK293T host cell line is an immortalized embryonic kidney epithelial line that stably expresses the SV40 large T antigen, supporting high-yield protein and virus production. Its robust growth and high transfection efficiency make it a standard platform for recombinant protein expression and lentiviral packaging. Endogenous non-muscle actin isoforms maintain essential cytoskeletal functions, allowing specific analysis of cardiac actin disruption without compromising cell viability.
Alpha-cardiac actin (ACTC1) is a sarcomeric thin filament protein critical for cardiac muscle contraction. Its expression is regulated by cardiac transcription factors NKX2-5, GATA4, MEF2C, and SRF, and the protein directly interacts with tropomyosin, troponin T (TNNT2), troponin I (TNNI3), troponin C (TNNC1), and myosin heavy chains (MYH6, MYH7) to mediate actin-myosin force generation. ACTC1 also binds alpha-actinin and nebulin for thin filament stabilization. CRISPR-mediated knockout of ACTC1 eliminates this cardiac-specific isoform, potentially altering actin polymerization kinetics and interactions with sarcomere-associated proteins even in non-muscle cells.
Although HEK293T cells lack organized sarcomeres, ACTC1 knockout provides a clean experimental system for dissecting isoform-specific roles of cardiac actin. This model enables precise examination of actin filament assembly, cell migration, and cytoskeletal architecture without interference from other sarcomeric proteins. Co-expression of interacting partners such as TNNT2, TNNI3, and MYH6 allows biochemical reconstitution of partial sarcomeric complexes. Furthermore, the knockout pool can be utilized in directed cardiac differentiation protocols to investigate the necessity of ACTC1 for sarcomere formation and contractile function in committed cardiomyocytes.
Representative applications include Western blotting and RT-qPCR for expression validation, immunofluorescence for actin architecture assessment, in vitro actin polymerization assays, cell migration assays, and co-immunoprecipitation for mapping protein?Cprotein interactions. These polyclonal knockout cells support population-based screening, lentivirus-mediated rescue experiments, and can be used as a precursor for monoclonal expansion if required. This product serves as a foundational tool for research into cardiac actin biology, cytoskeletal disorders, and cardiomyopathy signaling. For additional technical details, please contact Ascent Research.
